TauroPharm

TauroPharm We develop antimicrobial lock solutions for patients with central-venous catheters. Improving the patient’s quality of life remains our number-one priority.

Founded in 2000, TauroPharm GmbH is a German company specialising in medical devices with antimicrobial efficacy. As TauroLock™ solutions have been approved in expert guidelines, we continue to expand our international network. Our mission
TauroPharm aims to make the application of vascular access devices (VAD) easier and safer. We are developing more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Our products
We have created a range of lock solutions suitable for implanted central-venous catheters (CVC) and port systems. These products contain several ingredients to prevent catheter occlusion and catheter-related infections. Today, TauroLock™ solutions are recommended in interdisciplinary guidelines on a national and international scale. These include the ESPEN (European Society for Clinical Nutrition and Metabolism), GAVeCeLT (Italian association for long-term central-venous access devices), SFNCM (French Society of Clinical Nutrition and Metabolism), and DGfN (German Society of Nephrology). All TauroLock™ products have been investigated in clinical trials and are certified by regulatory bodies. Our sales network
As a manufacturer, TauroPharm focuses on four areas: product development, production, training, and quality management. To distribute our products, we collaborate with international partners who provide support and advice to customers in their respective countries. Our correspondents have been carefully selected and hold trust-based partnerships with healthcare professionals in nephrology, oncology, gastroenterology, intensive and palliative medicine, and home care. Our educational programmes
TauroPharm offers special training in all countries where TauroLock™ products are sold and implemented. These programmes help distributors familiarise themselves with our lock solutions and their application.

Próxima parada: ¡Valencia! Right after the EHRA Congress in France, we’ll be heading to Spain for the World Congress on ...
09/04/2026

Próxima parada: ¡Valencia!

Right after the EHRA Congress in France, we’ll be heading to Spain for the World Congress on Vascular Access in Valencia.

You can meet us and our partners from Bionet Medical S.L. at 𝗯𝗼𝗼𝘁𝗵 𝗕𝟯 from 15 through 17 April.

Don’t miss the chance to find the best option for preventing catheter-related complications in your field of expertise!

Paris, on y va ! The Congress of the European Heart Rhythm Association takes place in France this year, and we’ll be on ...
08/04/2026

Paris, on y va !

The Congress of the European Heart Rhythm Association takes place in France this year, and we’ll be on site along with our partners from AUXENS MÉDICAL.

If you’re attending, don’t miss the chance to visit us at booth D900 and learn all about TauroPace™: The solution to prevent CIED contamination.

12-14 April, booth D900 at the Palais des Congrès!

Clinically proven, recommended by experts: The 2+1 protocol is our first choice for haemodialysis patients. Prophylactic...
02/04/2026

Clinically proven, recommended by experts: The 2+1 protocol is our first choice for haemodialysis patients.

Prophylactic locking with TauroLock™-HEP500 2x weekly and TauroLock™-U25.000 1x weekly significantly reduces the rate of catheter-related complications. This regimen provides the strongest protection not only against infection, but also against thrombosis and dysfunction.*

Our website now includes a page where you can find all available materials on the 2+1 protocol, complete with an expert testimonial.

Link in comments! ⬇️

*Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026

Bye bye, WCN 2026, and bye bye to catheter-related complications… Very happy to part ways with the latter, but very sad ...
31/03/2026

Bye bye, WCN 2026, and bye bye to catheter-related complications… Very happy to part ways with the latter, but very sad the former’s already over.

The Congress delivered on all fronts: Fruitful conversations and intriguing presentations, interspersed with some glimpses of Japanese culture.

それでは、また次回!

19/03/2026

Big in Japan… with the International Society of Nephrology this year!

We are very much looking forward to attending the World Congress of Nephrology in Yokohama. 🙌

You can find us at 𝗯𝗼𝗼𝘁𝗵 𝗻𝗼. 𝟭𝟯 if you’d like to learn more about THE catheter lock solution for dialysis patients.

🗓️ March 28 through 31!

We got to spend some time with our partners from Crosstec last week, at a nephrology nursing conference in Vienna.  Big ...
10/03/2026

We got to spend some time with our partners from Crosstec last week, at a nephrology nursing conference in Vienna.

Big thank you to chairwoman Panagiota Tsikala for her persistent commitment to improving standards of care in dialysis. She has been making a big impact as the brand ambassador of EDTNA/ERCA in Austria.

Another big thank you to all the experts who visited our stand! We never stop learning from each other, and that’s exactly what we love about our job.

05/03/2026

TauroLock™-U25.000 is 𝘁𝗵𝗲 catheter lock solution for dialysis patients.

Used alone or as part of the 2+1 protocol*, it reliably prevents all kinds of catheter-related complications: Biofilm, infection, occlusion, thrombosis, malfunction, removal.

Proven in clinical trials. (1,2,3)

Recommended by experts. (4)

Are you ready to unlock the new standard of catheter management?

*TauroLock™-HEP500 2x weekly, TauroLock™-U25.000 1x weekly.

1) Al-Ali et al. Nephrol Dial Transplant 2018. DOI: 10.1093/ndt/gfx187
2) Bonkain et al. PLoS One 2021. DOI: 10.1371/journal.pone.0251793
3) Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026
4) Guideline in addition to the German dialysis standard. German Society of Nephrology (DGfN) 2019.

The superior catheter lock solution is based on 𝘁𝗮𝘂𝗿𝗼𝗹𝗶𝗱𝗶𝗻𝗲.  That’s the verdict of a systematic review and meta-analysi...
03/03/2026

The superior catheter lock solution is based on 𝘁𝗮𝘂𝗿𝗼𝗹𝗶𝗱𝗶𝗻𝗲.

That’s the verdict of a systematic review and meta-analysis published in 2026.
The review included 39 studies on 9 different types of lock solutions. In total, taurolidine-based solutions showed “𝘴𝘶𝘱𝘦𝘳𝘪𝘰𝘳 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺 𝘪𝘯 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘯𝘨 𝘊𝘓𝘈𝘉𝘚𝘐 𝘤𝘰𝘮𝘱𝘢𝘳𝘦𝘥 𝘵𝘰 𝘰𝘵𝘩𝘦𝘳 𝘪𝘯𝘵𝘦𝘳𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘴, 𝘱𝘢𝘳𝘵𝘪𝘤𝘶𝘭𝘢𝘳𝘭𝘺 𝘢𝘮𝘰𝘯𝘨 𝘩𝘪𝘨𝘩-𝘳𝘪𝘴𝘬 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘪𝘯𝘵𝘦𝘯𝘴𝘪𝘷𝘦 𝘤𝘢𝘳𝘦 𝘶𝘯𝘪𝘵𝘴 (𝘐𝘊𝘜𝘴) 𝘢𝘯𝘥 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘸𝘢𝘳𝘥𝘴”. They scored the highest probability of CLABSI reduction at 89.1 %.

Moreover, the review recognised their antibiofilm and anticoagulant efficacy (due to additional active ingredients), especially in paediatric patients and those on home parenteral nutrition.

The authors concluded that there is “𝘴𝘵𝘳𝘰𝘯𝘨 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘨𝘳𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 [𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦-𝘣𝘢𝘴𝘦𝘥 𝘭𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴] 𝘪𝘯𝘵𝘰 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘷𝘦𝘯𝘰𝘶𝘴 𝘤𝘢𝘵𝘩𝘦𝘵𝘦𝘳 𝘮𝘢𝘪𝘯𝘵𝘦𝘯𝘢𝘯𝘤𝘦 𝘣𝘶𝘯𝘥𝘭𝘦𝘴 𝘥𝘶𝘦 𝘵𝘰 𝘵𝘩𝘦𝘪𝘳 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘣𝘦𝘯𝘦𝘧𝘪𝘵𝘴”.

Source: Liu et al. J Vasc Access 2026. DOI: 10.1177/11297298251409615

The use of taurolidine-based lock solutions has become more and more prominent in ICU settings. As the Spanish Society o...
26/02/2026

The use of taurolidine-based lock solutions has become more and more prominent in ICU settings.

As the Spanish Society of Intensive and Critical Care Medicine and Coronary Care Units notes, “𝘵𝘩𝘦 𝘭𝘰𝘤𝘬𝘪𝘯𝘨 𝘰𝘧 𝘊𝘝𝘊𝘴 𝘸𝘪𝘵𝘩 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦 𝘪𝘴 𝘵𝘢𝘬𝘪𝘯𝘨 𝘰𝘯 𝘢𝘯 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘳𝘰𝘭𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘰𝘧 𝘊𝘙𝘉𝘚𝘐”.*

We have recently added a 𝗻𝗲𝘄 𝗽𝗮𝗴𝗲 𝘁𝗼 𝗼𝘂𝗿 𝘄𝗲𝗯𝘀𝗶𝘁𝗲 dedicated specifically to this field of application. It provides detailed information, along with studies and expert recommendations, on TauroLock™ solutions in the context of intensive care.

We hope it’s helpful for both professionals and patients!

⬇️ Link in comments.

*Spanish Society of Intensive and Critical Care Medicine and Coronary Care Units (Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias, SEMICyUC) 2022.

🎬 A little sneak peek behind the scenes...Turns out, our office kitchen makes for a great film studio!Guess what we were...
24/02/2026

🎬 A little sneak peek behind the scenes...

Turns out, our office kitchen makes for a great film studio!

Guess what we were up to? More coming soon…

20/02/2026

Prof. Dr. Gürkan Sengölge is a nephrologist with 20+ years of experience.

At the University Clinic in Vienna, he and his team reduced catheter-related complications in dialysis patients with a simple intervention: The so-called 2+1 protocol.

Prophylactic locking two times weekly with TauroLock™-HEP500, and once weekly with TauroLock™-U25.000.

The results:

⬇️ infection rate down by 75 % to 0.7 episodes per 1,000 catheter days

⬇️ dysfunction rate down by 60 %

⬇️ alteplase rescue rate down by 50 %

Total treatment costs dropped while the patients’ quality of life improved. They needed less interventions, less hospitalisations, and less catheter exchanges.

It was a simple change that made a big difference.

Want to achieve the same outcome for your patients? TauroLock™-U25.000 is available in your country through our exclusive partner.

Source: Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026

Saving lives with locked lines in Egypt. 🇪🇬 Last week, the Congress of the Egyptian Society of Nephrology and Transplant...
17/02/2026

Saving lives with locked lines in Egypt. 🇪🇬

Last week, the Congress of the Egyptian Society of Nephrology and Transplantation took place in Cairo.

Shout-out to Sameh Hamed and our partners from Paxton for representing TauroLock™ solutions (and educating visitors on the push-pause technique)!

Adresse

August-Bebel-Str. 51
Waldbüttelbrunn
97297

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von TauroPharm erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Praxis Kontaktieren

Nachricht an TauroPharm senden:

Teilen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram